122 related articles for article (PubMed ID: 38271745)
21. MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
Wong SK; Alex D; Bosdet I; Hughesman C; Karsan A; Yip S; Ho C
Lung Cancer; 2021 Apr; 154():142-145. PubMed ID: 33667719
[TBL] [Abstract][Full Text] [Related]
22. Impact of
Canale M; Petracci E; Delmonte A; Chiadini E; Dazzi C; Papi M; Capelli L; Casanova C; De Luigi N; Mariotti M; Gamboni A; Chiari R; Bennati C; Calistri D; Ludovini V; Crinò L; Amadori D; Ulivi P
Clin Cancer Res; 2017 May; 23(9):2195-2202. PubMed ID: 27780855
[No Abstract] [Full Text] [Related]
23. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.
Gainor JF; Rizvi H; Jimenez Aguilar E; Skoulidis F; Yeap BY; Naidoo J; Khosrowjerdi S; Mooradian M; Lydon C; Illei P; Zhang J; Peterson R; Ricciuti B; Nishino M; Zhang J; Roth JA; Grishman J; Anderson D; Little BP; Carter BW; Arbour K; Sauter JL; Mino-Kenudson M; Heymach JV; Digumarthy S; Shaw AT; Awad MM; Hellmann MD
Ann Oncol; 2020 Mar; 31(3):404-411. PubMed ID: 32067682
[TBL] [Abstract][Full Text] [Related]
24. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
25.
Feng H; Xu H; Shi X; Ding G; Yan C; Li L; Jian Z; Yang X; Guo H; Li F; Zhang J; Ren X
Front Biosci (Landmark Ed); 2023 Jul; 28(7):147. PubMed ID: 37525904
[TBL] [Abstract][Full Text] [Related]
26. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.
Shang K; Huang H; Xu Y; Liu Y; Lu Z; Chen L
BMC Cancer; 2022 Dec; 22(1):1295. PubMed ID: 36503478
[TBL] [Abstract][Full Text] [Related]
28. Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis.
Di Federico A; De Giglio A; Gelsomino F; Sperandi F; Melotti B; Ardizzoni A
J Natl Cancer Inst; 2023 Jan; 115(1):29-42. PubMed ID: 36322815
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
30. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
31. The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
Christopoulos P; Kluck K; Kirchner M; Lüders H; Roeper J; Falkenstern-Ge RF; Szewczyk M; Sticht F; Saalfeld FC; Wesseler C; Hackanson B; Dintner S; Faehling M; Kuon J; Janning M; Kauffmann-Guerrero D; Kazdal D; Kurz S; Eichhorn F; Bozorgmehr F; Shah R; Tufman A; Wermke M; Loges S; Brueckl WM; Schulz C; Misch D; Frost N; Kollmeier J; Reck M; Griesinger F; Grohé C; Hong JL; Lin HM; Budczies J; Stenzinger A; Thomas M
Eur J Cancer; 2022 Jul; 170():106-118. PubMed ID: 35598358
[TBL] [Abstract][Full Text] [Related]
32. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
33. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Kim H; Lim DH; Kwon YS; Kim MA; Park KU
Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of
Tønnesen EMT; Stougaard M; Meldgaard P; Lade-Keller J
J Clin Pathol; 2023 Dec; 77(1):54-60. PubMed ID: 36410939
[TBL] [Abstract][Full Text] [Related]
35. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
[TBL] [Abstract][Full Text] [Related]
36. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
Elkrief A; Alessi JMV; Ricciuti B; Brown S; Rizvi H; Preeshagul IR; Wang X; Pecci F; Di Federico A; Lamberti G; Egger JV; Chaft JE; Rudin CM; Riely GJ; Kris MG; Ladanyi M; Chen Y; Hellmann MD; Shen R; Awad MM; Schoenfeld AJ
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37487667
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitors treatment failure].
Wang C; Li Y; Guan Y; Yang SJ; Yin JC; Zhang CF; Guo QS; Shi WN
Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(16):1210-1216. PubMed ID: 37087404
[No Abstract] [Full Text] [Related]
39. Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients.
Liu J; Gao J
Eur J Cancer Prev; 2023 Nov; 32(6):590-599. PubMed ID: 37038985
[TBL] [Abstract][Full Text] [Related]
40. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
Zhang Y; Song L; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Wang Z; Xia Q; Jiang W; Xu Q; Yang N
BMC Cancer; 2022 Sep; 22(1):952. PubMed ID: 36064386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]